A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

Phase 1 Completed 55 enrolled Anaveon AG

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

Timeline

Start: 2021-05-25
Primary completion: 2024-07-18
Completion: 2024-07-18

Publications

Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral de la Fuente E, Hess D, Konig D, Sanchez Perez V, Bucher C, Jethwa S, Garralda E. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. J Immunother Cancer. 2023 Nov 21;11(11):e007784. doi: 10.1136/jitc-2023-007784.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ANV419	Protein / enzyme biologic	3 ug/kg	Intravenous
Subject	ANV419	Protein / enzyme biologic	6 ug/kg	Intravenous
Subject	ANV419	Protein / enzyme biologic	12 ug/kg	Intravenous
Subject	ANV419	Protein / enzyme biologic	243 ug/kg	Intravenous
Subject	Ipilimumab	Monoclonal antibody	—	Intravenous

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

Summary

Timeline

Publications

Drugs

Indications